ECSP088350A - Pirazolopirimidinas como inhibidores de protein quinasas - Google Patents

Pirazolopirimidinas como inhibidores de protein quinasas

Info

Publication number
ECSP088350A
ECSP088350A EC2008008350A ECSP088350A ECSP088350A EC SP088350 A ECSP088350 A EC SP088350A EC 2008008350 A EC2008008350 A EC 2008008350A EC SP088350 A ECSP088350 A EC SP088350A EC SP088350 A ECSP088350 A EC SP088350A
Authority
EC
Ecuador
Prior art keywords
compounds
inhibitors
methods
pirazolopirimidinas
protein kinases
Prior art date
Application number
EC2008008350A
Other languages
English (en)
Inventor
Timothy J Guzi
Michael Dwyer
Carmen S Alvarez
Kamil Paruch
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of ECSP088350A publication Critical patent/ECSP088350A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En sus muchas realizaciones, la presente invención provee una nueva clase de compuestos pirazolo[1,5-a]pirimidina amino-sustituidos como inhibidores de las proteínas y/o quinasas checkpoint, métodos para preparar dichos compuestos, composiciones farmacéuticas que incluyen uno o más de dichos compuestos, métodos para la preparación de las formulaciones farmacéuticas que incluyen uno o más de dichos compuestos, y métodos de tratamiento prevención, inhibición o mejoramiento de una o más enfermedades asociadas con las proteínas o checkpoint quinasas usando dichos compuestos o composiciones farmacéuticas.
EC2008008350A 2005-10-06 2008-04-04 Pirazolopirimidinas como inhibidores de protein quinasas ECSP088350A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72419705P 2005-10-06 2005-10-06

Publications (1)

Publication Number Publication Date
ECSP088350A true ECSP088350A (es) 2008-05-30

Family

ID=37560916

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008350A ECSP088350A (es) 2005-10-06 2008-04-04 Pirazolopirimidinas como inhibidores de protein quinasas

Country Status (18)

Country Link
US (1) US7776865B2 (es)
EP (1) EP1931676B1 (es)
JP (2) JP5052518B2 (es)
KR (1) KR20080063806A (es)
CN (1) CN101321760A (es)
AR (1) AR056206A1 (es)
AT (1) ATE533770T1 (es)
AU (1) AU2006299338A1 (es)
BR (1) BRPI0617150A2 (es)
CA (1) CA2624882C (es)
EC (1) ECSP088350A (es)
IL (1) IL190598A0 (es)
NO (1) NO20082092L (es)
PE (1) PE20070543A1 (es)
RU (1) RU2008117298A (es)
TW (1) TW200745123A (es)
WO (1) WO2007041712A1 (es)
ZA (1) ZA200802995B (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2624882C (en) * 2005-10-06 2014-05-20 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
BRPI0616985B1 (pt) * 2005-10-06 2021-10-26 Merck Sharp & Dohme Corp. Composto de pirazolo[1,5-a]pirimidina, e, uso de um composto
US20090069315A1 (en) * 2006-03-08 2009-03-12 Rajeev Sivasankaran Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders
KR20090019796A (ko) * 2006-05-22 2009-02-25 쉐링 코포레이션 ＣＤＫ 억제제로서의 피라졸로[1,5-ａ]피리미딘
ES2403546T3 (es) * 2006-11-03 2013-05-20 Pharmacyclics, Inc. Sonda de actividad de la tirosina-cinasa de Bruton y procedimiento de utilización
MY146474A (en) 2006-11-06 2012-08-15 Supergen Inc Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
NZ580982A (en) 2007-05-08 2012-05-25 Schering Corp Methods of treatment using intravenous formulations comprising temozolomide
US8124759B2 (en) 2007-05-09 2012-02-28 Abbott Laboratories Inhibitors of protein kinases
MX2009012079A (es) * 2007-05-09 2009-11-19 Abbott Lab Compuestos heterociclicos condensados como inhibidores de proteina cinasas.
WO2008141140A1 (en) * 2007-05-09 2008-11-20 Abbott Laboratories Condensed heterocyclic compounds as inhibitors of protein kinases
EP2170886A1 (en) 2007-07-02 2010-04-07 Cancer Research Technology Limited 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors
AR069198A1 (es) * 2007-11-07 2010-01-06 Schering Corp Derivados de ribosil pirimidinas moduladores de quinasas de control chk1,y composiciones farmaceuticas que los comprenden utiles en el tratamiento del cancer.
US8426441B2 (en) * 2007-12-14 2013-04-23 Roche Palo Alto Llc Inhibitors of bruton's tyrosine kinase
CN101952283B (zh) * 2007-12-14 2013-04-17 霍夫曼-拉罗奇有限公司 咪唑并[1，2-a]吡啶和咪唑并[1，2-b]哒嗪衍生物
EP2265603B1 (en) 2008-03-13 2014-05-07 The General Hospital Corporation Inhibitors of the bmp signaling pathway
CN102088853A (zh) * 2008-05-12 2011-06-08 安内斯蒂克斯公司 改善学习和记忆的化合物
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
PA8851101A1 (es) * 2008-12-16 2010-07-27 Lilly Co Eli Compuesto amino pirazol
KR20110114663A (ko) * 2009-02-13 2011-10-19 바이엘 파마 악티엔게젤샤프트 융합된 피리미딘
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
UA110324C2 (en) * 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
EP2473041B1 (en) 2009-09-04 2018-03-07 Merck Sharp & Dohme Corp. Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
JP5607174B2 (ja) * 2009-12-01 2014-10-15 アッヴィ・インコーポレイテッド 新規な三環式化合物
US20130184273A1 (en) * 2010-07-13 2013-07-18 Bayer Intellectual Property Gmbh Bicyclic pyrimidines
ES2539257T3 (es) * 2010-07-28 2015-06-29 Bayer Intellectual Property Gmbh Imidazo[1,2-b]piridazinas sustituidas
JP2014517079A (ja) 2011-06-22 2014-07-17 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
EP2734205B1 (en) 2011-07-21 2018-03-21 Tolero Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors
JP6073910B2 (ja) 2011-11-09 2017-02-01 キャンサー・リサーチ・テクノロジー・リミテッド ５−（ピリジン−２−イル−アミノ）−ピラジン−２−カルボニトリル化合物及びその治療使用
CN104066736B (zh) * 2012-01-10 2017-03-08 拜耳知识产权有限责任公司 作为akt激酶抑制剂的取代的吡唑并嘧啶
JP6027230B2 (ja) 2012-05-15 2016-11-16 キャンサー・リサーチ・テクノロジー・リミテッド ５−［［４−［［モルホリン−２−イル］メチルアミノ］−５−（トリフルオロメチル）−２−ピリジル］アミノ］ピラジン−２−カルボニトリルおよびその治療上の使用
SMT202000713T1 (it) 2012-12-07 2021-03-15 Vertex Pharma Pirazolo [1,5-a] pirimidine utili come inibitori dell'atr chinasi per il trattamento di malattie del cancro
EP2943485B1 (en) 2013-01-14 2017-09-20 Incyte Holdings Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
ME03780B (me) 2013-01-15 2021-04-20 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
US9682983B2 (en) 2013-03-14 2017-06-20 The Brigham And Women's Hospital, Inc. BMP inhibitors and methods of use thereof
JP2016512815A (ja) 2013-03-15 2016-05-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
EP2970288A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2014143241A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2015008844A1 (ja) 2013-07-18 2015-01-22 大鵬薬品工業株式会社 Ｆｇｆｒ阻害剤耐性癌の治療薬
KR101974254B1 (ko) 2013-07-18 2019-04-30 다이호야쿠힌고교 가부시키가이샤 Fgfr 저해제의 간헐 투여용 항종양제
TW201605866A (zh) 2013-08-23 2016-02-16 英塞特公司 可用作ｐｉｍ激酶抑制劑之呋喃并－及噻吩并－吡啶甲醯胺化合物
HUE046727T2 (hu) 2013-12-06 2020-03-30 Vertex Pharma Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai
CN107074863B (zh) 2014-06-05 2019-12-03 沃泰克斯药物股份有限公司 Atr激酶抑制剂的制备方法及其不同的固体形式
PL3157566T3 (pl) 2014-06-17 2019-10-31 Vertex Pharma Metoda leczenia nowotworu przy użyciu kombinacji inhibitorów chk1 i atr
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
WO2016011019A1 (en) 2014-07-15 2016-01-21 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting bmp
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
MX373612B (es) 2015-03-31 2020-05-07 Taiho Pharmaceutical Co Ltd Cristal del compuesto alquinil benceno 3,5-disustituido.
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
KR102678021B1 (ko) 2015-09-30 2024-06-26 버텍스 파마슈티칼스 인코포레이티드 Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
EP3424505A4 (en) 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
WO2018215389A1 (en) * 2017-05-22 2018-11-29 F. Hoffmann-La Roche Ag Therapeutic compounds and compositions, and methods of use thereof
WO2019023468A1 (en) 2017-07-28 2019-01-31 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
EP4470621A3 (en) 2018-03-19 2025-05-07 Taiho Pharmaceutical Co., Ltd. Use of sodium alkyl sulfate
CA3095580A1 (en) 2018-04-13 2019-10-17 Sumitomo Dainippon Pharma Oncology, Inc. Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer
CN108586341B (zh) * 2018-05-25 2020-05-08 天津商业大学 酰胺类化合物和其药用盐及其制备方法和药物用途
CA3115088A1 (en) * 2018-10-15 2020-04-23 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
CN109293630A (zh) * 2018-11-15 2019-02-01 山东大学 含取代吡唑类化合物及其制备方法与应用
AU2020221247B2 (en) 2019-02-12 2024-12-12 Sumitomo Pharma America, Inc. Formulations comprising heterocyclic protein kinase inhibitors
CN112457306A (zh) 2019-09-06 2021-03-09 上海瑛派药业有限公司 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
TW202204348A (zh) 2020-04-07 2022-02-01 美商西爾拉癌症醫學公司 Ｃｈｋ１抑制劑之合成方法
CN114957261B (zh) * 2022-05-17 2023-06-23 重庆文理学院 一种具有抗头颈癌作用的化合物及其制备方法和应用
JP2026509318A (ja) 2022-10-31 2026-03-18 スミトモ・ファーマ・アメリカ・インコーポレイテッド 骨髄増殖性新生物を治療するためのｐｉｍ１阻害剤
WO2025162425A1 (zh) * 2024-02-01 2025-08-07 广州费米子科技有限责任公司 吡唑并嘧啶化合物作为tyk2抑制剂

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3130633A1 (de) * 1981-08-01 1983-02-17 Basf Ag, 6700 Ludwigshafen 7-amino-azolo(1,5-a)pyrimidine und diese enthaltende fungizide
WO1992018504A1 (en) 1991-04-22 1992-10-29 Otsuka Pharmaceutical Factory, Inc. PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE AND ANTI-INFLAMMATORY CONTAINING THE SAME
EP0628559B1 (en) 1993-06-10 2002-04-03 Beiersdorf-Lilly GmbH Pyrimidine compounds and their use as pharmaceuticals
US5571813A (en) 1993-06-10 1996-11-05 Beiersdorf-Lilly Gmbh Fused pyrimidine compounds and their use as pharmaceuticals
KR100315837B1 (ko) 1994-06-21 2002-02-28 고리 히데아끼 피라졸로[1,5-a]피리미딘유도체
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
JP2002501532A (ja) 1997-05-30 2002-01-15 メルク エンド カンパニー インコーポレーテッド 新規血管形成阻害薬
DE69837282T2 (de) 1997-12-13 2007-11-08 Bristol-Myers Squibb Co. VERWENDUNG VON PYRAZOLO Ä 3,4-bÜ PYRIDIN ALS CYCLIN-ABHÄNGIGE KINASE HEMMER
US6413974B1 (en) 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
DK1140938T3 (da) 1999-01-11 2003-12-22 Univ Princeton Højaffinitetsinhibitorer for målvalidering og anvendelser heraf
FR2805160B1 (fr) * 2000-02-23 2002-04-05 Oreal Compositions pour la teinture d'oxydation des fibres keratiniques comprenant un n(2-hydroxybenzene)-carbramate ou un n-(2-hydroxybenzene)-uree et une pyrazolopyrimidine, et procedes de teinture
CN100457753C (zh) 2000-07-26 2009-02-04 布里斯托尔-迈尔斯斯奎布公司 依赖细胞周期蛋白的激酶的n－[5－[[[5－烷基－2－唑基]甲基]硫代]－2－噻唑基]甲酰胺抑制剂
EP1317453B1 (en) 2000-09-15 2006-08-09 Vertex Pharmaceuticals Incorporated Isoxazoles and their use as inhibitors of erk
US7067520B2 (en) 2000-11-17 2006-06-27 Ishihara Sangyo Kaisha, Ltd. Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts
JP2002212076A (ja) * 2000-11-17 2002-07-31 Ishihara Sangyo Kaisha Ltd 縮合複素環化合物またはその塩を含有する糖尿病の予防または治療薬
CA2432417A1 (fr) 2000-12-20 2002-06-27 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R .A.S.) Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
KR20040097375A (ko) 2002-04-23 2004-11-17 시오노기 앤드 컴파니, 리미티드 피라졸로[1, 5-에이]피리미딘 유도체 및 이를 함유한엔에이디(피)에이취 산화효소 저해제
DE10223917A1 (de) 2002-05-29 2003-12-11 Bayer Cropscience Ag Pyrazolopyrimidine
EP1511751B1 (en) 2002-06-04 2008-03-19 Neogenesis Pharmaceuticals, Inc. Pyrazolo[1,5-a]pyrimidine compounds as antiviral agents
MXPA05002571A (es) * 2002-09-04 2005-09-08 Schering Corp Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina.
WO2004089416A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
AR049769A1 (es) * 2004-01-22 2006-09-06 Novartis Ag Derivados de pirazolo(1,5-a)pirimidin 7-il-amina para utilizarse en el tratamiento de enfermedades dependientes de la quinasa de proteina
ATE448229T1 (de) * 2005-01-19 2009-11-15 Merck & Co Inc Bicyclische pyrimidine als dipeptidylpeptidase-iv-hemmer zur behandlung bzw. prävention von diabetes
GB0515026D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
CA2624882C (en) * 2005-10-06 2014-05-20 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors

Also Published As

Publication number Publication date
AR056206A1 (es) 2007-09-26
PE20070543A1 (es) 2007-06-14
EP1931676A1 (en) 2008-06-18
CA2624882A1 (en) 2007-04-12
ZA200802995B (en) 2009-02-25
WO2007041712A1 (en) 2007-04-12
US7776865B2 (en) 2010-08-17
RU2008117298A (ru) 2009-11-20
JP5052518B2 (ja) 2012-10-17
US20070083044A1 (en) 2007-04-12
ATE533770T1 (de) 2011-12-15
BRPI0617150A2 (pt) 2011-07-12
CA2624882C (en) 2014-05-20
TW200745123A (en) 2007-12-16
KR20080063806A (ko) 2008-07-07
CN101321760A (zh) 2008-12-10
JP2012082233A (ja) 2012-04-26
IL190598A0 (en) 2008-11-03
JP2009511491A (ja) 2009-03-19
NO20082092L (no) 2008-07-04
AU2006299338A1 (en) 2007-04-12
EP1931676B1 (en) 2011-11-16

Similar Documents

Publication Publication Date Title
ECSP088345A (es) Nuevas pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
TW200745128A (en) Pyrazolopyrimidines as protein kinase inhibitors
ATE420883T1 (de) Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
TW200745123A (en) Pyrazolopyrimidines as protein kinase inhibitors
BRPI0511616A (pt) compostos
ECSP11005642A (es) Nuevos pirazolopirimidinas como inhibidores de quinasa dependientes de ciclinas
DK1812440T3 (da) Pyrazolo[1,5-a]pyrimidiner, der kan anvendes som inhibistorer af proteinkinaser
ECSP088906A (es) PIRAZOLO 1,5-a PIRIMIDINAS
TW200745127A (en) Pyrazolopyrimidines as protein kinase inhibitors
MX2009013729A (es) Imidazopirazinas como inhibidores de proteina quinasa.
BRPI0509369A (pt) azaindóis úteis como inibidores de jak e outras proteìna cinases
ECSP077985A (es) Inhibidores de proteina cinasa derivados de pirrol (2,3-b) piridina
NO20071915L (no) Diaminotriazolforbindelser nyttige som proteinkinaseinhibitorer
ECSP077324A (es) Amidas bicíclicas como inhibidores de cinasa
NZ590258A (en) Kinase inhibitors and methods of use
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
EA201790995A1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ
DK1537116T3 (da) Pyrazolopyrimidiner egnede til behandling af cancersygdomme
PL2201840T3 (pl) Inhibitory kinazy tyrozynowej Brutona
DE602007007985D1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
PH12014500053A1 (en) Proteasome inhibitors
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
ECSP066763A (es) Pirazolopirimidinas novedosas como inhibidores de quinasa ciclina-dependientes
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer